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INTRODUCTION 
 
A tremendous growth in the proportion of elderly people 
raises a range of challenges to societies worldwide. 
Healthy aging should therefore be a main priority for all 
countries across the globe. However, science behind the 
study of age-associated diseases is increasing and 
common molecular mechanisms that could be used to 
dissect longevity pathways and develop safe and 
effective interventions for aging are being explored. In 
this regard, novel methodologies using the power of 
artificial intelligence (AI) are emerging to cope with the 
massive amount of data that are becoming available [1]. 
A collaborative effort based on transfer of technology 
and knowledge between academia and industry is also 
needed to accelerate aging discoveries and facilitate 
better transition of effective interventions into clinics. To 
accelerate this, the Aging Research and Drug Discovery 
(ARDD) meeting was founded seven years ago in Basel, 
Switzerland. This year‟s meeting, organized by Alex 
Zhavoronkov, Insilico Medicine, Morten Scheibye-
Knudsen, University of Copenhagen and Daniela Bakula, 
University of Copenhagen, was particularly challenging 







 of September 2020, moved online with 
local hosting at the University of Copenhagen. We were 
very fortunate to have 65 fantastic speakers and more 
than 2200 „ARDDists‟ (Figure 1). This report provides an 
overview of the presentations covering topics on some of 
the latest methodologies to study aging, molecular 
characterization of longevity pathways, existing aging 
interventions and the importance of aging research for the 
global society and economy. 
Novel approaches to study aging 
 
The progress in discoveries of basic mechanisms of 
aging as well as development of novel interventional 
strategies depends primarily on approaches and tools 
that are used in the lab. During the last couple of 
decades, methodological strategies for emerging big 
data from various cell-, tissue- and organ-types have 
accelerated towards development of high-throughput 
screening techniques and computational approaches 
using the power of artificial intelligence [1]. However, 
despite the capacity of data analysis, existing methods 
are constantly improving and becoming integrated as a 
part of intervention-screening platforms. Martin Borch 
Jensen, Gordian Biotechnology, San Francisco, USA, 
presented their approach for conducting high-
throughput screens of many therapies in a single animal, 
using single-cell sequencing. By identifying cells within 
a diseased tissue that appear healthy after receiving one 
of many interventions, they are able to test in vivo 
efficacy of therapies much faster than traditional drug 
development. Another achievement in the development 
of advanced technology has been made in the area of 
proteomics, discussed by Andreas Mund, University of 
Copenhagen, Denmark. In particular, single cell 
proteomes can be analysed to extract valuable 
information regarding disease mechanisms. Its integ-
ration with multiplexed imaging of human-derived 
tissue samples and deep learning techniques enables the 
creation of an advanced deep visual proteomics pipeline 
for discovery of novel biomarkers and effective 
therapeutics that could potentially be used in clinics [2]. 
Further, Ieva Bagdonaite, University of Copenhagen, 
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Aging is emerging as a druggable target with growing interest from academia, industry and investors. New 
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Denmark, underlined the value of investigating protein 
glycosylation that undergoes dynamic changes in age-
associated diseases, as well as highlighted the 
importance of mapping complex glycoproteome using 
advanced quantitative proteomics for both developing 
efficient therapies and biomarker discovery [3]. 
 
Benefits of omics-based big data analysis were also 
presented by Christian Riedel, Karolinska Institutet, 
Sweden, who developed an advanced screening approach 
for geroprotector discovery. In this approach, screening 
of novel compounds is based on the transcriptome 
analysis of human tissues from people of varying ages 
and the application of machine learning to create age 
classifiers that predict biological age [4]. He looks for 
compounds that can shift transcriptomes of “older” 
towards “younger” tissues and thereby identifies drug 
candidates with potential geroprotective capabilities. 
Transcriptomics and other omics-based tools are also 
actively used by Vadim Gladyshev‟s team, Brigham  
and Women‟s Hospital, Harvard Medical School,  
USA. Particularly, comparative analysis of global 
transcriptomics and metabolomics data across species 
with different lifespan, across known longevity 
interventions, and across cell types with different lifespan 
can be used to develop an unbiased approach for the 
discovery of novel longevity interventions [5, 6]. Such 
approach can be intensely applied to determine the 
relationship among different types of interventions and its 
association with lifespan extension [7]. Identification of 
common signatures of longevity also raises great 




Figure 1. Statistics from ARDD2020. 
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compounds that are candidates for lifespan extension. 
Besides interventions, genetic studies enable the 
identification of novel factors contributing to aging. 
Using available genotyping data and genetic traits from 
two human cohort studies, ultra-rare damaging mutations 
were identified including rarest protein-truncating 
variants that negatively affect lifespan and healthspan [8]. 
Interestingly, genetic variation that supports longevity is 
also protective against COVID-19, which emerges as a 
disease of aging [9, 10]. A genetic approach to 
understand aging in humans was also described by 
Yousin Suh, Columbia University, USA. Studies of 
common and rare genetic variants in centenarians can be 
used to dissect longevity-associated genetic variants that 
may potentially be applied to understand the molecular 
basis of healthy aging as well as to develop new therapies 
for improving healthspan [11, 12]. 
 
Novel animal models are also being explored for the 
study of aging. Dario Riccardo Valenzano, Max Planck 
Institute for Biology of Ageing, Cologne, Germany, 
demonstrated how host-microbiota interactions can be 
important determinants for maintaining homeostasis  
and modulating lifespan using the short-lived model 
organism African turquoise killifish [13, 14]. He showed 
that fecal transplantation of young microbiota to old 
animals rescued age-dependent decrease in abundance of 
microbiota and extended the lifespan of the fish. 
Modulation of microbial function can also impact the 
effect of potential pharmacological interventions in 
hosts, as was highlighted by Filipe Cabreiro, Imperial 
College London, UK, who suggested that age-dependent 
changes in gut microbial composition can be potentially 
considered one of the hallmarks of aging [15]. Using  
the well-known pro-longevity drug metformin and a 
combination of model organisms such as C. elegans  
and D. melanogaster together with computational 
approaches for modelling human microbiome data, 
Filipe‟s team showed that diet can impact the beneficial 
effect of metformin. His team developed a high-
throughput screening platform to identify dietary 
metabolites and microbial molecular pathways that are 
responsible for the effect of metformin on health- and 
lifespan [16]. In worms, this and other potential aging 
interventions can be tested using a novel approach to 
measure health by atomic force microscopy based on the 
assessment of worm stiffness and cuticle senescence 
(roughness) across age spectrum [17]. 
 
Deep aging clocks 
 
Application of artificial intelligence for the development 
of novel therapeutics and biomarker discovery have been 
actively highlighted during the ARDD meeting. In 
particular, for the last couple of years several aging 
clocks have been developed to predict chronological and 
biological age based on certain clinical parameters [18]. 
Steve Horvath, University of California, Los Angeles, 
USA, demonstrated their importance in predicting not 
only chronological age, but also mortality risks across 
mammalian species referring to second generation 
epigenetic clocks, including PhenoAge and GrimAge 
[19, 20]. The translational value of epigenetic clocks was 
also highlighted in regard to testing aging interventions 
and their application in clinical trials [21]. The 
assessment of health state and life expectancy using deep 
learned clocks was further presented by Alice Kane, 
Harvard, USA. She developed a deep learned aging 
measure using a frailty index as a fast non-invasive 
mortality predictor for mice [22]. Another talk on 
estimation of chronological age was given by Anastasia 
Georgievskaya, Haut.AI, Tallinn, Estonia. Anastasia 
took an advantage of face and hand images from 
different age groups to create multimodal age prediction 
analyses as a part of a pipeline for the development of 
non-invasive visual biomarkers of human aging [23]. 
The importance of deep learning applications in 
healthcare and biomarker discovery was also discussed 
by Polina Mamoshina, Deep Longevity, Hong Kong. In 
particular, because different biological aging clocks may 
be associated with different aging processes, Deep 
Longevity aims to combine multiple clocks to estimate 
and monitor biological age over time [18, 24]. 
 
Interestingly, in humans, drug repurposing and its 
efficiency can be estimated not only by applying various 
aging clocks, but also using life-course trajectories and 
health-to-disease transition analyses presented by Søren 
Brunak from Novo Nordisk Foundation Center for 
Protein Research, University of Copenhagen, Denmark 
[25]. Using large datasets on millions of patients, this in 
silico approach enables the understanding of how one 
disease follows another and estimates if certain genes are 
linked to diseases [26]. The use of single patient disease 
trajectories spanning up to 20 years when predicting 
intensive care mortality highlighted how aging data and 
machine learning can be made actionable at the bedside 
as opposed to statistical assessment of larger groups of 
individuals [27]. 
 
Genome maintenance in aging and longevity 
 
Age-dependent alterations in cellular pathways lead to a 
decline in organ function and progression of disease. 
Understanding what causes aging and examining 
common patterns of changes on gene, protein and post-
translational levels during the lifespan and across 
multiple tissues is one of the challenging tasks for aging 
researchers. Jan Vijg, Albert Einstein College of 
Medicine, USA, underlined that somatic mutations, 
including point mutations and genomic rearrangements, 
accumulate during aging and may contribute to mortality 
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and disease [28]. Applying single-cell sequencing allows 
the identification of an age-dependent exponential 
increase in mutation frequency in human B lymphocytes 
[29] and liver hepatocytes [30], and propose mechanisms 
of how de novo mutations accumulate from early 
embryogenesis to adulthood and old age, and lead to the 
development of disease [28]. A topic of chromosomal 
aging was also highlighted in regard to reproductive 
lifespan by Eva Hoffmann, University of Copenhagen, 
Denmark. Investigations of changes in fertility rate 
during aging showed that chromosome errors and 
aberrations in oocytes control natural fertility in humans 
[31]. Based on current knowledge of genetic regulation 
of reproductive aging, interventions for pregnancy loss 
are being developed and were discussed during the 
ARDD meeting. 
 
Interestingly, a genetic network that controls reproductive 
aging and somatic maintenance is primarily related to 
pathways associated with DNA repair and cell cycle 
regulation. Substantial research in aging has been done 
towards investigating nuclear DNA damage, which 
associates with multiple hallmarks of aging [32], as  
well as developing interventional strategies for protecting 
the aging genome [33]. Björn Schumacher, University of 
Cologne, Germany, characterized molecular 
consequences of DNA damage either in germline or 
somatic cells [34, 35] and examined molecular pathways 
that regulate somatic maintenance using C. elegans as a 
model organism. His recent discovery of epigenetic 
modifiers that are required for maintaining lifespan after 
DNA damage [36] shed light on novel molecular 
pathways linking DNA damage, epigenetics and 
longevity. A connection between DNA damage/repair, 
post-translational modifications and longevity was also 
presented by Vera Gorbunova, University of Rochester, 
USA, who applies a comparative biology approach to 
study short- and long-lived animals. Her team showed 
that the DNA double strand break (DSB) repair 
efficiency shows strong positive correlation with 
maximum lifespan across mammalian species. Higher 
DNA repair efficiency in long-lived species was, in large 
part, due to the higher activity of the histone deacetylase 
and mono-ADP-rybosylase, Sirtuin 6 (SIRT6) [37]. 
Vera‟s talk also included unpublished data in humans 
showing that rare missense mutations in SIRT6 sequence 
identified in human centenarians are associated with 
more efficient DNA DSB repair. The functional role of 
SIRT6 in DNA repair also includes acting as a sensor of 
DSB, observed by Debra Toiber, Ben Gurion University 
of the Negev, Israel. Her data illustrates that SIRT6 
directly binds to DNA, is recruited to the site of damage 
independently of PARP, MRE11 and KU80 and triggers 
activation of a DNA damage response [38]. Considering 
that SIRT6 depletion leads to accelerated aging and 
neurodegeneration phenotypes in mice, targeting it could 
be a potential strategy for the development of novel 
neuroprotective therapeutics [39, 40]. 
 
Importantly, genome maintenance and age-dependent 
changes in gene expression patterns are primarily 
dependent on chromatin state and epigenetic 
modifications [41]. David Sinclair, Harvard, USA, 
showed that DSBs may drive age-dependent epigenetic 
alterations and loss of cellular identity. Using a 
transgenic mouse system for inducible creation of DSBs, 
he revealed that loss of epigenetic structures, an 
accumulation of epigenetic noise and increased predicted 
DNA methylation changes increase with age and DNA 
damage [42, 43]. Importantly, the introduction of an 
engineered vector expressing Yamanaka transcription 
factors, excluding c-Myc, regenerated axons after optic 
nerve crush injury and restored vision in old mice [44]. 
The effect was dependent on the DNA demethylases 
Tet1, Tet2 and TDG and was accompanied by a reversal 
of methylation patterns and resetting the DNA 
methylation clock. Interestingly, epigenetic modifications 
in aging were studied also in other model organisms. In 
worms, one of the euchromatin-associated epigenetic 
marks known to affect lifespan is H3K4me3, controlled 
by the COMPASS complex [45]. Carlos Silva Garcia, 
Harvard, USA, showed that COMPASS-related longevity 
in C. elegans is dependent on activation of SREBP1, a 
master regulator of lipid metabolism leading to an 
increase in monosaturated fatty acids that is required for 
lifespan extension in COMPASS-deficient C.elegans 
[45], and presented novel data on the involvement of 
CREB-regulated transcriptional coactivator CRTC1 in 
COMPASS-mediated lifespan extension [46]. Here, 
Alexey Moskalev, the Russian Academy of Sciences, 
Russia, discussed mechanisms associated with lifespan-
prolonging effects of chromatin modifier E(z) histone 
methyltransferases in D. melanogaster. The increase in 
lifespan of heterozygous E(z) mutant flies is associated 
with higher resistance to different stressors and changes 
in expression of genes related to immune response, cell 




Longevity-associated molecular pathways are actively 
being explored in different model organisms. In rodents, 
differential gene expression in multiple tissues were 
described by David Glass from Regeneron, Inc., USA. 
Studies revealed an increase in gene expression 
variability during aging where bioenergetics pathways 
were identified to be significantly down-regulated in 
kidney, skeletal muscle and liver, while inflammatory 
signaling was upregulated in these tissues [48]. While 
old animals demonstrated increased activity of 
mammalian Target Of Rapamycin (mTOR) in skeletal 
muscle, it was highlighted that mTOR needs to be down-
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regulated for healthspan benefits but not completely 
inhibited. By using rapalogs, inhibitors of mTOR, the 
authors observed improvements in the kidney of old rats 
and identified key regulators, including c-Myc, that are 
involved in the beneficial effect of mTOR inhibition 
[49]. In a mouse study, partial mTOR down-regulation 
was also shown to be beneficial for skeletal muscle – 
decreasing degeneration/regeneration, and, surprisingly, 
increasing skeletal muscle mass [50]. Another 
mechanism by which down-regulation of mTOR 
signaling leads to longevity, was presented by Collin 
Ewald, ETH Zurich, Switzerland. Collin‟s team 
discovered a hydrogen sulfide pathway as a potential 
longevity mechanism that is up-regulated by ATF4 in 
dietary restriction (DR) as a stress response to a decrease 
in global mRNA translation [51]. Interestingly, hydrogen 
sulfide has already been shown to possess beneficial 
effects in age-related diseases with currently running 
clinical trials for cardio-vascular improvements 
(NCT02899364 and NCT02278276). However, in 
addition to activation of hydrogen sulfide signaling, 
decreased mRNA translation and ATF4 expression have 
a strong regulatory link to the mitochondrial translation 
machinery that was also shown to impact longevity [52]. 
Riekelt Houtkooper, Amsterdam UMC, Netherlands 
showed that down-regulation of mitochondrial ribosomal 
proteins extends lifespan [52] and presented novel  
data that disruption of mitochondrial dynamics [53] 
synergizes with reduced mitochondrial mRNA 
translation in C.elegans [54]. Marte Molenaars, 
Amsterdam UMC, Netherlands demonstrated that there 
is a balance between mRNA translation in the cytosol 
and in mitochondria, and inhibiting mitochondrial 
translation leads to the repression of cytosolic translation 
and lifespan extension via atf-5/ATF4 [55]. 
 
Another molecular mechanism tightly related with 
mitochondria and other organelles maintenance that is 
impaired during aging is autophagy [56]. Ana Maria 
Cuervo, Albert Einstein College of Medicine, USA, 
presented the importance of selective, and in particular, 
chaperone-mediated autophagy (CMA) in aging and 
age-related diseases [57]. Her recently developed mouse 
model to monitor CMA in vivo revealed that CMA 
activity is activated upon starvation in multiple organs, 
but that there are cell-type specific differences in this 
response [58]. CMA decline in most organs and tissues 
at different rate and contributes to loss of proteostasis 
and subsequent cell function. In the case of neurons, 
reduced CMA in mice leads to gradual alterations in 
motor-coordination and cognitive function suggesting 
that targeting selective autophagy can be a treatment 
option in neurodegenerative diseases [59]. Anais Franco 
Romero, University of Padova, Italy, presented data on 
the identification of novel FOXO-dependent genes that 
are related to longevity. One of the hits, the MYTHO 
gene, was found to be highly up-regulated in old mice 
and humans compared to young ones, and is associated 
with impairments in the autophagy machinery and motor 
function alterations in C. elegans and D. Rerio model 
organisms. A novel mechanism linking lysosomal 
function and mitochondria was presented by Nuno 
Raimundo, Universitätsmedizin Göttingen, Germany, 
who studied the consequences of impaired lysosomal 
acidification in aging and the development of 
neurodegeneration. Specifically, the data illustrates that 
blockage of lysosomal acidification via vATPase 
inhibition leads to the accumulation of iron in lysosomes 
and cellular iron deficiency resulting in impaired 
mitochondrial function and development of 
inflammation both in cultured neurons and in the brain 
of mice [60]. 
 
Importantly, because multiple cellular maintenance 
pathways associated with longevity requires high energy 
consumption, mitochondrial function can be considered 
to possess a pivotal role to affect biological aging. Luigi 
Ferrucci, National Institute on Aging - NIH, USA, 
highlighted that restoration of mitochondrial biogenesis 
and function may be achieved by temporary but not 
long-term blockage of major energy-consuming 
regulatory pathways. More specifically, Luigi‟s talk was 
aimed at explaining why mitochondrial function declines 
with age and presented evidence of reduced resting 
muscle perfusion, altered lipid biosynthetic pathways 
and impaired activity of the carnitine shuttle [61, 62]. 
 
Lifestyle strategies for metabolic interventions 
 
Identification of longevity-associated molecular 
pathways and the discovery of novel biomarkers of 
human aging goes along with the development of 
effective strategies for interventions. Currently, multiple 
interventions have been developed to target cellular 
metabolism, which is considered to possess a critical 
function in aging process [63]. Lifestyle interventions, 
including diet and its nutrient composition, regulate 
metabolic balance and affect lifespan across different 
species. Andrey Parkhitko, University of Pittsburgh, 
USA, discussed the role of the non-essential amino acid 
tyrosine in aging. In fly experiments, tyrosine levels 
decrease with age, accompanied by an increase of 
tyrosine-catabolic pathways. Preliminary data revealed 
that down-regulation of enzymes of tyrosine 
degradation, including the rate-limiting tyrosine 
aminotransferase (TAT), extends the lifespan of D. 
Melanogaster [64]. How protein affects lifespan has 
been further explored by Dudley Lamming, University 
of Wisconsin, USA [65]. Dudley‟s team dissected the 
role of essential dietary amino acids in regulating 
lifespan. Reduction of branched chain amino acids 
(Leucine, Isoleucine and Valine) increases metabolic 
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health, reducing adiposity and improving glucose 
tolerance in mice [66]. Further studies revealed that the 
low BCAA diet possess geroprotective properties, 
extending the lifespan of two progeroid mouse models, 
improving metabolic health in wild-type mice 
throughout their lifespan, and extending the lifespan and 
reducing the frailty of wild-type male, but not female, 
mice. These effects may be mediated in part by a sex-
specific effect of a low BCAA diet on mTORC1 
signaling [67]. Furthermore, Heidi Pak, University of 
Wisconsin, USA, illustrated that fasting is required for 
the beneficial effect of caloric restriction on healthspan 
and lifespan (unpublished data). Specifically, fasting was 
necessary to detect improvements in insulin sensitivity 
and to obtain the distinct metabolomic and 
transcriptomic signatures observed in caloric restricted 
male mice. Similarly, Pam Taub, UC San Diego, USA 
described the beneficial role of fasting as a part of 
lifestyle strategies for patients with cardiometabolic 
disease [68]. Importantly, the circadian rhythm was 
highlighted to have an important role for driving 
metabolism and affecting the efficiency of interventions. 
One dietary intervention that does not affect the 
robustness of the circadian rhythm is time-restricted 
eating (TRE). Pam‟s recently published study illustrated 
that 10 h TRE can be used as a safe and effective 
lifestyle intervention, together with standard medications 
that are applied for treatment of cardiometabolic 
syndrome. However, besides metabolic diseases, fasting 
and caloric restriction display beneficial effects also in 
diseases associated with premature aging. Jan 
Hoeijmakers, Erasmus Medical Center Rotterdam, 
Netherlands, presented data that caloric restriction 
positively affects behavior and extends the lifespan in 
ERCC1-deficient progeroid mice, and reduces tremors 
and improves the cognitive function in a human patient. 
 
Another lifestyle intervention that has a beneficial role 
for healthy aging is exercise. Thomas Rando, Stanford, 
USA, underlined the regenerative potential of skeletal 
muscles from young species that decline during aging. 
He showed that exercise in the form of running improves 
functionality of muscle stem cells almost to the level of 
young cells and increases the aged muscle capacity to 
repair injury in mice [69]. The improved function of 
muscle stem cells in old animals after exercise was 
associated with up-regulation of Cyclin D1, suppression 
of TGFbeta signaling and an exit from quiescence [69]. 
However, besides a decreased capacity of muscle 
regeneration, a decline in muscle function is also known 
to occur during aging. Gerard Karsenty, Columbia 
University, USA highlighted that age-dependent decline 
in muscle function and exercise capacity can be restored 
using osteocalcin. Circulating levels of this bone-derived 
hormone dramatically decreases already in middle age, 
surges after running and this hormone favors muscle 
function during exercise without affecting muscle mass, 
through two mechanisms in part. First, osteocalcin 
signaling in myofibers promotes uptake of glucose and 
fatty acids and the catabolism of these nutrients to 
produce ATP molecules needed for muscle function 
during exercise. Second, osteocalcin signaling in 
myofibers up-regulates the release in the circulation of 
muscle-derived interleukin-6 that in a feed forward loop 
increases the release of osteocalcin by bone during 
exercise and thereby exercise capacity [70]. Injection of 
osteocalcin increases the exercise capacity, fully restores 
muscle function and increases muscle mass in aged mice 
[70, 71]. Recent data also revealed that osteocalcin 
outperforms one of the leading compounds that is being 
tested for sarcopenia already in late clinical trials. 
 
Benefits of exercise training for muscle function were 
also described in the context of maintenance of 
nicotinamide adenine dinucleotide (NAD
+
) metabolism 
by Jonas Thue Treebak, University of Copenhagen, 
Denmark. A rate-limiting enzyme of NAD
+
 metabolism, 
nicotinamide phosphoribosyltransferase (NAMPT), 
declines with age and was shown to be the only enzyme 
from the NAD
+
 salvage pathway that is restored by 
aerobic and resistance exercise training in human 
skeletal muscle [72]. Recent studies revealed that 
knockout of NAMPT in mouse skeletal muscle leads to 
a strong reduction in muscle function, dystrophy and 
premature death, suggesting a crucial role of NAMPT 
for maintaining NAD
+ 
levels in skeletal muscle. 
 
Pharmacological approaches to modulate 
healthspan and lifespan 
 
Molecular and therapeutic importance of NAD
+
 
metabolism for aging was underlined in multiple talks at 
the ARDD meeting. Eric Verdin, Buck Institute, USA 
introduced the concept of competition among major 
NAD
+
-utilizing enzymes for NAD
+
 that may explain its 
age-dependent decline across multiple tissues [73]. The 
main focus of the talk was CD38, a NAD
+
-metabolizing 
enzyme that increases with age in adipose tissues [74]. 
Verdin‟s team discovered that CD38 activity is 
increased in M1 macrophages during aging and its 
activation depended on key cytokines from the 
senescence-associated secretory phenotype (SASP) 
secreted by senescent cells. Brenna Osborne, University 
of Copenhagen, Denmark further illustrated that 
depletion of CD38 appears to exacerbate some of the 
aging phenotypes in the mouse model of Cockayne 
syndrome, where another major NAD
+
-utilizing enzyme 
poly(ADP) ribose polymerase 1 (PARP1), is 
hyperactivated. Overall, current data suggest that a 
crosstalk between NAD
+
-utilizing enzymes needs to be 
continuously investigated in order to develop safe and 
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However, precursors of NAD
+ 
are actively being tested 
in various age-associated disorders. Evandro Fei Fang, 
University of Oslo, Norway underlined the importance 
of the NAD
+
-mitophagy/autophagy axis in aging and 
neurodegeneration and presented data on how 
impairment of this axis contributes to the progression in 
accelerated aging diseases as well as in the most 
common dementia, the age-predisposed Alzheimer‟s 
disease [75, 76]. Induction of mitophagy either by 
NAD
+ 
or other mitophagy stimulators inhibits amyloid-
beta and p-Tau aggregates, as well as improves memory 
impairments in several models of Alzheimer‟s disease 
[77, 78]. Similar results were observed by Lene Juel 
Rasmussen from Center for Healthy Aging, University 
of Copenhagen, Denmark. Lene‟s team uses in vitro and 
in vivo animal models with a deficiency in the DNA 
repair gene REV1, which causes replication stress and 
premature aging. Suppression of REV1 is associated 
with high PARP1 activity, low endogenous NAD
+
 and 
low SIRT1 expression [79]. Presented data showed that 
mitochondrial dysfunction and morphology changes 
were suppressed, and autophagy was increased after 
nicotinamide riboside (NR) supplementation in REV1-
deficient cells and that NR increased the lifespan and 
healthspan of REV1-deficient nematodes. Importantly, 
the underlying cause of the development of premature 
aging disorders described before are impairments in 
genes associated with DNA repair [80]. Morten 
Scheibye-Knudsen, University of Copenhagen, 
Denmark, demonstrated the importance of targeting 
DNA repair for healthy aging and illustrated how the 
power of AI can be applied to find novel DNA repair 
stimulators. Particularly, an in silico approach enabled 
the identification of novel compounds that are able to 
delay replicative aging and reverse senescent 
phenotypes in multiple primary cells, as well as 
improve the behavior and extend the lifespan in wild-
type D. Melanogaster (unpublished data). 
 
Another recently uncovered molecule that is able to 
improve mitochondrial function via mitophagy is 
Urolithin A, a gut microbiome metabolite known to 
improve mitochondrial function via mitophagy, increases 
muscle function and possesses geroprotective features 
across multiple species [81]. Pénélope Andreux, 
Amazentis, Switzerland presented results from a double 
blinded placebo controlled study showing that urolithin A 
administration in healthy elderly people is safe and was 
bioavailable after single or multiple doses over a 4-week 
period [82]. Oral consumption of urolithin A decreased 
plasma acylcarnitines, a sign of improved systemic 
mitochondrial function, and displayed transcriptomic 
signatures of improved mitochondrial and cellular health 
in muscle. Interventions targeting autophagy pathways 
were also highlighted by Rafael de Cabo, National 
Institute on Aging-NIH, USA, in the context of obesity 
and metabolic health. Recent data showed that disulfiram 
treatment prevents high-fat diet-induced obesity in mice 
by reducing feeding efficiency, decreasing body weight, 
and increasing energy expenditure [83]. Moreover, 
disulfiram prevents pancreatic islet hyperplasia and 
protects against high-fat diet-induced hepatic steatosis 
and fibrosis. Further experiments uncovered common 
molecular signatures after disulfiram treatment, revealing 
pathways associated with lipid and energy metabolism, 
redox, and detoxification and identified autophagy as one 
of the key targets by which disulfiram mediates its 
beneficial effects in cell culture [84]. The link between 
metabolic health and age-related bone loss was 
highlighted by Moustapha Kassem, Molecular 
Endocrinology Unit, University of Southern Denmark, 
Denmark, who suggested targeting skeletal mesenchymal 
stem cells (MSC) for the treatment of age-related 
osteoporosis. A decline in bone marrow composition, as 
well as alterations in the function of MSC in bone 
remodelling, are known to occur during aging [85]. The 
Kassem team identified the KIAA1199 protein to be 
highly secreted from hMSCs during osteoblast 
differentiation in vitro [86] and is associated with 
recruitment of hMSC to bone formation sites [85]. 
 
Another “classical” pro-longevity pathway that is 
explored for the development of aging interventions is 
the IGF signaling pathway. For example, targeting 
IGFBP-specific PAPP-A protease using genetically 
modified mouse models leads to lifespan extension [87, 
88]. Here, Adam Freund, Calico Life Sciences LLC, 
USA, investigated targeting PAPP-A using antibodies. 
RNA sequencing revealed treatment with anti-PAPP-A 
to down-regulate collagen and extracellular matrix genes 
across multiple tissues. Further investigations identified 
MSCs to be a primary responder to PAPP-A inhibition. 
Restraining MSC activity is likely to be a mechanism 
driving a systemic response of tissues to PAPP-A 
inhibition. However, further experiments are required for 
the development of safe and effective therapeutic 
strategies for reducing IGF signaling. 
 
Importantly, IGF-1 and other pro-aging factors may 
trigger activation of the NF-kB signaling cascade 
leading to inflammation and the development of 
senescent phenotypes, suggesting that NF-kB plays a 
key role in modulating the aging process [89, 90]. Lei 
Zhang, University of Minnesota, USA, applied an in 
silico approach to screen compounds capable of 
disrupting IKKβ and NEMO association thereby 
inhibiting NF-kB transcriptional activation [91]. A small 
molecule called SR12343 was identified to suppress 
lipopolysaccharide (LPS)-induced acute pulmonary 
inflammation in mice and attenuate necrosis and muscle 
degeneration in a mouse model of Duchenne muscular 
dystrophy [91]. SR12343 also attenuated senescent cell 
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phenotypes in vitro as well as in mouse models of 
premature aging. A late life intervention with SR12343 
in naturally aged mice demonstrated a decrease in 
senescent markers in liver and muscle. Hence, 
pharmacological targeting of NF-kB activation offers 
considerable potential for improving healthspan. 
 
Interventions targeting senescent cells 
 
Notably, studies of multiple interventions in different 
aging models include examinations of various markers 
of cellular senescence. Its significance for the aging 
process has been shown multiple times across model 
systems [92]. Senescent cells occur in all organs, 
including post-mitotic brain tissues, during aging and at 
sites of age-related pathologies. The SASPs of senescent 
cells lead to chronic inflammation and may contribute to 
the development of various cellular phenotypes 
associated with aging and diseases. Hence, a novel class 
of drugs targeting senescent cells are emerging, 
including senolytics (selective elimination of senescent 
cells) and senomorphics (selective modification of 
senescent cells). However, it should be considered that 
cellular senescence is a balancing act between its 
beneficial and detrimental roles in maintaining tissue 
homeostasis, as described by Judith Campisi from Buck 
Institute, USA. For instance, removal of senescent cells 
by senolytic drugs is one strategy to combat aging 
phenotypes [93]. However, no single senolytic drug 
eliminates all senescent cells, likely due to the 
heterogeneity among cells and distinct cell-type specific 
differences and variations in the SASP [94]. Moreover, it 
was highlighted that the SASP also varies depending on 
the senescence inducer [93] underlining the question: 
“what drives cells into senescence during natural 
aging?”. In particular, this question was addressed by 
Kotb Abdelmohsen, National Institute on Aging - NIH, 
USA, who presented data on the identification of a 
transcriptome signature of cellular senescence based on 
RNA sequencing [95]. His team identified the 
microRNA miR-340-5p to be highly expressed in 
senescence triggered by several inducers across multiple 
cell types. MiR-340-5p promotes senescence through the 
downstream effector Lamin B receptor (LBR). They also 
discovered that miR-340-5p is senolytic-associated or 
senomiR that sensitizes senescent cells to senolytic 
drugs. 
 
Several strategies were proposed to target senescent 
cells. Marсo Demaria, ERIBA, Netherlands, 
demonstrated the important role of oxygen in the 
development of the senescence phenotype [96]. Data 
illustrated that growth arrest, lysosomal activity and 
DNA damage signalling were similarly activated in 
senescent cells cultured at 1% or 5% oxygen, but 
induction of the SASP was suppressed by low oxygen. 
Tissues exposed to low oxygen also expressed a lower 
SASP than more oxygenated ones. It was demonstrated 
that hypoxia restrains SASP via AMPK activation and 
mTOR inhibition, and that intermittent treatment with 
hypoxia mimetic compounds can serve as a potential 
strategy for the reduction of SASP in vivo. Further, Peter 
de Keizer, University Medical Center Utrecht, 
Netherlands underlined again the problem of the 
existence of distinct subtypes of cellular senescence and 
the absence of senescence-specific markers. A strategy 
of FOXO4-p53 targeting using a designed FOXO4 
peptide and other FOXO4-p53 inhibitory compounds 
can be applied to selectively eliminate senescence cells 
that appear during aging, as well as “senescence-like” 
chemoresistant cancer cells [97]. Laura Niedernhofer, 
University of Minnesota, USA, demonstrated a senolytic 
activity of fisetin, a natural flavonoid that improves the 
health- and lifespan in mouse models of normal and 
accelerated aging [98]. It was highlighted that several 
clinical trials with fisetin, also in regard to COVID-19, 
are under way. 
 
Another application of small molecules, resveralogues, 
to target senescent cells by reversing their phenotype 
was presented by Richard Faragher, University of 
Brighton, UK [99]. A range of compounds based on 
resveratrol were able to reverse senescent phenotypes 
and restore proliferative capacity by altering mRNA 
splicing and moderating splicing factor levels [100]. 
Those compounds that were also able to activate SIRT1 
demonstrated greater abilities to rescue cells from the 
senescence state [101]. 
 
Interestingly, screening of novel molecules using 
advanced AI-based tools and targeting senescent cells is 
also emerging. Carolina Reis, OneSkin, USA, underlined 
the importance of skin aging and illustrated why 
targeting senescent cells with novel senotherapeutic 
compounds can promote skin health in order to delay the 
onset of age-related diseases. Cell-based drug screening 
identified a lead compound, OS-1, that was able to 
reduce senescent cell burden and protect cells from 
UVB-induced photoaging. In addition, OS-1 was shown 
to reduce the molecular age of the skin using their 
developed skin-specific epigenetic clock [102] and 
showed benefits for skin health in a clinical study. 
Further experiments are being performed to examine 
whether OS-1 affects lifespan and healthspan in model 
organisms. 
 
Besides that application of lifestyle strategies that in 
many cases can mimic pharmacological therapies or 
possess synergetic effects for healthspan and lifespan, 
one should consider more upstream events on the level of 
prediction of disease. In this regard, development of non-
invasive biomarkers for human aging acquires special 
 
www.aging-us.com 24494 AGING 
significance. Majken Jensen, University of Copenhagen, 
Denmark illustrated the value of investigating high-
density lipoprotein (HDL) in the context of cardiovascular 
diseases and demonstrated HDL containing apoC3 to be 
the only subtype of HDL that was associated with higher 
risk of heart disease [103]. The problem of missing stable 
biomarkers for dementia prediction and Alzheimer 
disease was also underlined in Jensen‟s talk. Recently, 
published data revealed plasma apoE in HDL and lacking 
apoC3 was associated with lower dementia risk and 
better cognitive function [104]. This and other novel 
biomarkers for Alzheimer disease can be discovered 
using non-targeted proteomic profiling in cerebrospinal 
fluid (CSF) [105]. The importance of aging of the 
tissue producing the CSF was further demonstrated  
by Nanna MacAulay, University of Copenhagen, 
Denmark. Alterations associated with dysregulation  
of CSF can lead to several pathologies, including 
stroke-related brain edema and hydrocephalus. Water 
cotransporter mechanisms, rather than conventional 
osmotic driving forces, were highlighted to play a crucial 
role in the production of CSF and secretion from the 







(NKCC1) was identified to mediate approximately half of 
the CSF production, and thus provides opportunities for 
developing novel interventional strategies for pathologies 
associated with elevated brain fluid levels [106]. 
 
Challenges in aging: science, society and economy 
 
Currently, our understanding of the molecular basis of 
aging and age-associated diseases is improving. 
However, challenges in the aging field exist and refer to 
both science and society in general. Nir Barzilai, Albert 
Einstein College of Medicine, USA, highlighted several 
concerns including (1) the translational value of 
identified longevity mechanisms and effective 
interventions from animals to humans, (2) the discovery 
of reliable biomarkers for estimation of efficiency of 
various therapies and (3) the existence of possible 
antagonistic effects between different gerotherapeutics. 
Importantly, these challenges may be overcome because 
evolutionarily conserved molecular signatures of 
longevity between humans and animals have been 
identified (unpublished) and novel aging biomarkers that 
distinguish specific signatures of longevity are emerging 
[107]. Current knowledge also highlights careful 
consideration of the combination of geroprotectors that 
potentially may not lead to synergistic effects, with the 
example of the known pro-longevity drug metformin 
[108]. Additionally, COVID-19 research was mentioned 
in regard to the study of aging as an opportunity to 
advance geroscience. Aubrey de Grey from SENS 
Research Foundation, USA, also highlighted this topic 
and underlined the importance of thinking about 
COVID-19 in a broader way to target not only the 
immune system but aging in general, which raises a 
challenge to disseminate this knowledge to the public to 
raise awareness of the biology of aging and the 
possibility of interventions. Hence, novel strategies need 
to be implemented in order to engage the public into the 
field of aging. 
 
Another challenging topic discussed by Brian Kennedy, 
National University of Singapore, Singapore, related to 
the pros and cons of different ways of testing longevity 
interventions. Aging interventions would benefit most 
by applying prevention-based approaches and biomarker 
discovery [109]. Understanding how different 
physiological measures and aging clocks correspond to 
each other could allow targeted testing of different types 
of aging interventions, including the recently published 
life-extending molecule 2-oxoglutarate [110]. Further, 
João Pedro de Magalhães, University of Liverpool, UK, 
touched upon the topic of longevity interventions and 
highlighted the exponential growth of pharmacological 
approaches (DrugAge database), while research in genes 
associated with longevity have plateaued in recent years 
(GenAge database). Such shift towards drug discovery is 
accompanied by the appearance of an anti-aging biotech 
sector that could bring huge economic benefits in the 
future [111]. However, the lifespan of anti-aging 
companies is relatively small due to limitations in the 
time and ability to validate interventions, likely related 
to a lack of reliable aging biomarkers. Hence, in silico-
based approaches are being applied to overcome such 
limitations to identify either novel genes associated with 
aging phenotypes [112] or discover drug candidates for 
life extension [113]. 
 
AI in aging and longevity 
 
At the meeting several talks have been presented 
showing the power of AI in healthcare and the longevity 
industry. Kai-Fu Lee, Sinovation Ventures and 
Sinovation AI Institute, China explained different 
aspects of artificial intelligence and underlined deep 
learning to possess amazing attributes and provide great 
opportunities for the longevity sector. Particularly, deep 
learning is emerging in every aspect of healthcare and 
could advance longevity research with new analyses of 
omics-based big data. Different types of deep learning, 
including reinforcement learning and transfer learning, 
were highlighted in the context of building a 
knowledge-based network for health status prediction. 
Machine learning techniques are also used to develop a 
broad range of aging clocks that can be pooled together 
to conduct AgeMetric, a master predictor of the heath 
state of an individual [114]. Application of AgeMetric 
scores were further discussed by Alex Zhavoronkov, 
Insilico Medicine, Hong Kong who presented how AI-
based drug discovery can lead to commercial innovation 
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in longevity. In particular, next generation AI 
accelerates multiple aspects of biotechnology, including 
identification of novel targets, a rapid development of 
small molecules based on known targets [115] and 
prediction of outcomes of clinical trials. AI outperforms 
in many aspects humans if enough data is provided. By 
using different types of data and training a network on 
relatively healthy people, it is possible to re-train the 
network on particular disease and identify features that 
are specific to the diseases. Application of Agemetric 
scores and other AI-powered preventive medicine 
strategies in longevity medicine not only enables the 
prediction of biological age and tracking of healthy 
state, but also can be used to understand whether an 
individual is aging faster and how to intervene and slow 
down aging. 
 
The power of big data was also underlined by Wei-Wu 
He, Human Longevity Inc., USA, who discussed using  
big data to personalize aging interventions. These 
included not only omics data but also whole-body 
imaging techniques such as MRI. The possibility of 
combining very large amount of data is a unique 
opportunity for tailor made longevity solutions for every 
individual [116]. 
 
Sergey Young, Longevity Vision Fund, USA, further 
unravelled key driving forces within the longevity 
sector and explained why it is a favorable time to invest 
in the industry. This includes the appearance of several 
breakthrough innovations and a growing number of 
elderly people, along with an exponential increase in the 
prevalence of chronic age-related disease and unhealthy 
lifestyle. Further, the integration of AI and technology 
into medicine, healthcare and the longevity space will 
likely lead to business opportunities. All this is 
accompanied by an increase in capital and favourable 
support in the context of policies and regulations by the 
government. 
 
Last, Jim Mellon, Juvenescence, UK talked about how 
Juvenescence focuses on ways for improving human 
healthspan with the mission to extend healthy lifespan 
by 8-10 years in the upcoming future. It was highlighted 
that the biotech world possesses high risks with further 
complications in predictions of outcomes and 
achievements. One of the strategies to overcome such 
limitations is investment in multiple higher risk projects, 
with the likelihood that one or two of them will succeed. 
An important aspect of funded projects is the application 
of AI to accelerate drug development and bring drugs to 
market as quickly as possible. A Juvenescence pipeline 
includes focusing on diseases that have a major 
commercial impact on pro-longevity effects later on, 
with the example of targeting chronic kidney disease, 
Alzheimer disease and liver disease. In addition, a 
fruitful partnership with leading experts in aging and 
pharma companies facilitates upcoming fully developed 




Current knowledge shows that aging is a very complex 
but plastic process. Conserved molecular pathways 
underlining aging can be manipulated using genetic, 
pharmacological and non-pharmacological approaches 
to significantly improve the healthspan and lifespan in 
model organisms, and perhaps humans. A collaborative 
effort between academic research with a growing 
number of emerging biotech companies, as well as 
increased investment funds to accelerate discoveries, 
will most likely bring effective aging pharmaceuticals 
in the near future. Undoubtedly, we will see more in the 
coming ARDD meeting in September 2021 in New 
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We dedicate this meeting summary to Jay Mitchell who 
was a treasured colleague and who passed away too 
early. We will miss him dearly. 
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